An evidence based model with superior outcomes
We achieve better results across all
diabetes-related outcomes
Decrease in weight
Decrease in HbA1c
Decrease in triglycerides
Decrease in LDL cholesterol
Decrease in cardiovascular disease risk
Decrease in cholesterol
Zakaria et al., Diabetes Technol Obes Med. 2025;1(1):171–83. doi:10.1089/dtom.2025.0020
More touchpoints, better outcomes: the power of engagement in diabetes care
The more patients interacted with our care team, the better their results—across HbA1c, BMI, and waist circumference. Those with over 120 touchpoints in 12 months saw the greatest improvements, proving that consistent support drives real change.
That being said, we provide you with unlimited engagement with an entire care team.
Zakaria et al., Diabetes Technol Obes Med. 2025;1(1):171–83. doi:10.1089/dtom.2025.0020
Stable sugar, shifting costs: the hidden dynamics of diabetes treatment
Patients with HbA1c > 7.5% showed a clear link: lower HbA1c meant lower medication costs.
Zakaria et al., Diabetes Technol Obes Med. 2025;1(1):171–83. doi:10.1089/dtom.2025.0020
Our obesity outcomes
in 3 months
in 6 months
in 9 months
Improved key health markers
- 85.7% of members with prediabetes reversed their HbA1c back to normal
- In just 3 months, 49.5% of members got their cholesterol levels back to normal
- Reduced waist circumference:
–11.4 cm on average
Tirzepatide outperforms according to our data
- Superior to Semaglutide (ozempic) across all metrics
- More fat loss, greater muscle preservation
Fat % decreased, muscle maintained
- Fat mass: –9.9 kg on average
- Muscle mass preserved with structured care
Our prediabetes outcomes
We reverse pre-diabetes better than anyone globally
In just 3 months,
81%
of our prediabetic patients reversed their condition to a healthy clinical profile
HbA1c (%)
Weight (kg)
Cholesterol (mg/dl)
Triglycerides (mg/dl)
LDL (mg/dl)
Fat mass (kg)
Zakaria et al. Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study. Metab Open. 2024, doi:10.1016/j.metop.2024.100283.
Our CVD outcomes
Decrease in LDL cholestrol (mg/dl)
Decrease in cholestrol (mg/dl)
Decrease in cardiovascular disease risk
Decrease in triglycerides (mg/dl)
Decrease in inflammation
Zakaria et al, Frontiers in Endocrinology Volume 15 – (2024), doi: 10.3389/fendo.2024.1355792
We use less medication to treat
metabolic dysfunction
Patients reduced multi-medication regiments to single doses or eliminated medications altogether.
Zakaria et al., Diabetes Technol Obes Med. 2025;1(1):171–83. doi:10.1089/dtom.2025.0020